Connect Total Liab from 2010 to 2024
| CNTB Stock | USD 0.98 0.02 2.00% |
Total Liabilities | First Reported 2010-12-31 | Previous Quarter 24.8 M | Current Value 23.6 M | Quarterly Volatility 296.5 M |
Check Connect Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Connect Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 20.2 K, Other Operating Expenses of 76.5 M or Tax Provision of 114 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.68. Connect financial statements analysis is a perfect complement when working with Connect Biopharma Valuation or Volatility modules.
Connect | Total Liab |
Latest Connect Biopharma's Total Liab Growth Pattern
Below is the plot of the Total Liab of Connect Biopharma Holdings over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Connect Biopharma's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Connect Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Total Liab | 10 Years Trend |
|
Total Liab |
| Timeline |
Connect Total Liab Regression Statistics
| Arithmetic Mean | 474,401,956 | |
| Geometric Mean | 252,899,041 | |
| Coefficient Of Variation | 62.51 | |
| Mean Deviation | 261,964,058 | |
| Median | 670,875,000 | |
| Standard Deviation | 296,545,035 | |
| Sample Variance | 87939T | |
| Range | 654.1M | |
| R-Value | (0.83) | |
| Mean Square Error | 30152.1T | |
| R-Squared | 0.68 | |
| Significance | 0.0002 | |
| Slope | (54,745,132) | |
| Total Sum of Squares | 1231145.4T |
Connect Total Liab History
About Connect Biopharma Financial Statements
Connect Biopharma stakeholders use historical fundamental indicators, such as Connect Biopharma's Total Liab, to determine how well the company is positioned to perform in the future. Although Connect Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Connect Biopharma's assets and liabilities are reflected in the revenues and expenses on Connect Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Connect Biopharma Holdings. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Liabilities | 24.8 M | 23.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:Check out the analysis of Connect Biopharma Correlation against competitors. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.39) | Revenue Per Share 0.438 | Return On Assets (0.12) | Return On Equity (0.18) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.